Drugs / IMU-131
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02795988 | Aug 2017 → Mar 2024 | adenocarcinoma, digestive system neoplasm | Imugene Limited | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05311176 | Aug 2022 → Apr 2024 | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Imugene Limited | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMU-131 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02795988 ↗ |
| Known as | HER-Vaxx | “therapeutic B-cell epitope vaccine (IMU-131/HER-Vaxx) consisting of three fused B-cell epitopes from the HER2/neu extracellular domain coupled to CRM197 and adjuvanted with Montanide.” PMID 33879458 ↗ Apr 2021 |
| Action | Inhibit | “had a significant capacity in inhibiting phosphorylation of the intracellular HER2-signaling pathways” PMID 39028916 ↗ Sep 2024 |
| Modality | Vaccine | “a B-cell, peptide-based vaccine targeting HER2 overexpressed in 6% to 30% of gastroesophageal adenocarcinomas (GEA).” PMID 39028916 ↗ Sep 2024 |
| Route | Intramuscular | “administered intramuscularly into the deltoid region of the arm” NCT05311176 ↗ |